IQVIA and Pierre Fabre Pharmaceuticals Expand Relationship to Deploy IQVIA’s Orchestrated Customer Engagement
Innovative Solution Connects Commercial Functions and Channels for Improved Customer Interactions
DANBURY, Conn. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)-- IQVIA (NYSE:IQV), a company dedicated to using analytics and science to help healthcare stakeholders find better solutions for patients, and Pierre Fabre Pharmaceuticals, a subsidiary of Pierre Fabre S.A. and the 2nd largest French private pharmaceutical group, today announced plans to implement IQVIA’s new commercial technology solution, Orchestrated Customer Engagement (OCE). The new offering, uniquely adapted for the life sciences industry, connects marketing, sales and other critical business functions, enabling all departments to collaborate more effectively and optimize customer interactions.
Under the terms of this seven-year agreement, Pierre Fabre Pharmaceuticals will migrate all of its current CRM users to OCE, which Pierre Fabre Pharmaceuticals selected because of its strong “platform of platforms” foundation and open architecture. Pilot programs will begin early in Germany, France and Portugal, followed by the roll-out of OCE in the 30 additional countries where Pierre Fabre operates.
“By expanding our relationship with IQVIA, we will be able to realize our vision for field collaboration,” said Frédéric Duchesne, President and Chief Executive Officer, Pierre Fabre Pharmaceuticals. “Finally, we can bring together marketing, sales force, key account and access managers – all the actors working together to bring solutions to the patients and information to healthcare professionals. This is just a first step in building a continuum for better clinical trials and easier access to drugs for patients – as well as better execution with stronger ROI for us.”
Orchestrated Customer Engagement, built on best-in-class technologies such as Salesforce.com, Mulesoft, Amazon Web Services, Heroku and others, provides seamless integration across a “platform of platforms.” The solution leverages IQVIA’s Ada™, artificial intelligence that gives users recommendations for next-best actions; Apollo™, an intuitive user interface; and Lexi™, an application program interface (API) layer to connect all applications and data using common language. Life sciences companies are able to implement OCE with IQVIA or with other providers certified within the Salesforce.com ecosystem.
“We are proud to have Pierre Fabre as a strategic IQVIA customer, and we are pleased that they will be the first global company to deploy our new OCE technology,” said Alistair Grenfell, IQVIA President, Northern Europe, Middle East, South Asia and Africa. “We will work together on streamlining the value chain from clinical trials to commercial – from molecule to market – to the benefit of patients, HCPs, and pharmaceutical companies.”
IQVIA is committed to developing innovative technology solutions that help life sciences converge functional silos, integrate processes, strengthen customer relationships, and more effectively anticipate and respond to market changes. Additional information about OCE is available on the IQVIA website.
Today’s announcement of the availability of Orchestrated Customer Engagement will culminate with a state-of-the-art event for industry executives, editors and analysts, at the Bellevue Hotel in Philadelphia, from 4:00 to 7:00 PM.
About Pierre Fabre
Pierre Fabre is a French private pharmaceuticals and dermo-cosmetics company founded in 1962 by Mr. Pierre Fabre. Its turnover reached over 2.28 billion Euros in 2016, spread over 130 countries. The company is structured around two divisions: Pharmaceuticals (prescription drugs, consumer health care) and Dermo-cosmetics (including the Europe and Asia market-leader Eau Thermale Avène brand). Pierre Fabre employs some 13,000 people worldwide and owns subsidiaries in 47 countries. In 2016, the company allocated 14% of its pharmaceuticals sales to R&D with a focus on 4 therapeutic areas: oncology, dermatology, CNS and consumer health care.
Pierre Fabre Laboratories have always developed durable and valuable scientific partnerships with innovators from public research institutions (CRNS, Inserm...), faculties and universities (Ecole Polytechnique de Lausanne, Université de Saclay...), international pharmaceutical laboratories (Allergan, Abbvie, Maruho...) and biotech companies (Array BioPharma, AbCheck, Cellectar...).
Through the Group’s controlling company Pierre Fabre Participations, Pierre Fabre is 86% owned by the Pierre Fabre Foundation, a recognized public-interest organization since 1999. Up to 8.2% of the remaining shares are held by the company’s employees and the remaining balance is held as treasury stock.
To find out more about Pierre Fabre, please go to www.pierre-fabre.com .
IQVIA (NYSE:IQV) is a leading global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find better solutions for their patients. Formed through the merger of IMS Health and Quintiles, IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward. IQVIA enables companies to rethink approaches to clinical development and commercialization, innovate with confidence as well as accelerate meaningful healthcare outcomes. IQVIA has approximately 55,000 employees in more than 100 countries, all committed to making the potential of human data science a reality. IQVIA’s approach to human data science is powered by the IQVIA CORE™, driving unique actionable insights at the intersection of big data, transformative technology and analytics with extensive domain expertise.
IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing the information that helps their customers drive human health outcomes forward. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.IQVIA.com.